ID   Hs
AC   CVCL_W404
SY   HS
DR   CGH-DB; 9-1
DR   CGH-DB; 9161-4
DR   Wikidata; Q54895339
RX   PubMed=7530506;
RX   PubMed=10936422;
RX   PubMed=15215163;
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 21-03-23; Version: 6
//
RX   PubMed=7530506; DOI=10.1182/blood.V85.3.757.bloodjournal853757;
RA   Shima Y., Nishimoto N., Ogata A., Fujii Y., Yoshizaki K.,
RA   Kishimoto T.;
RT   "Myeloma cells express Fas antigen/APO-1 (CD95) but only some are
RT   sensitive to anti-Fas antibody resulting in apoptosis.";
RL   Blood 85:757-764(1995).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//